# Efficacy of Ursodeoxycholic Acid (UDCA) in Patients With Type 2 Diabetes

> **NCT05416580** · PHASE3 · UNKNOWN · sponsor: **University of Banja Luka** · enrollment: 60 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** UDCA (Ursodeoxycholic acid)
- **DRUG:** Placebo
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT05416580
- **Lead sponsor:** University of Banja Luka
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-12
- **Primary completion:** 2024-03
- **Final completion:** 2024-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05416580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05416580, "Efficacy of Ursodeoxycholic Acid (UDCA) in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05416580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*